INS and type 2 diabetes mellitus: Although CGM was previously reported to be cost‐effective compared to SMBG in patients with type 1 or type 2 diabetes on insulin therapy,67, 68, 69, 70 these studies were mostly conducted in developed countries, and relevant data in China is scarce.